KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $1.7 billion.

  • Pfizer's Depreciation & Amortization (CF) fell 529.91% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $4.9 billion, marking a year-over-year decrease of 2882.02%. This contributed to the annual value of $7.0 billion for FY2024, which is 1149.44% up from last year.
  • Per Pfizer's latest filing, its Depreciation & Amortization (CF) stood at $1.7 billion for Q3 2025, which was down 529.91% from $1.6 billion recorded in Q2 2025.
  • Pfizer's Depreciation & Amortization (CF)'s 5-year high stood at $3.9 billion during Q4 2021, with a 5-year trough of $1.2 billion in Q3 2022.
  • In the last 5 years, Pfizer's Depreciation & Amortization (CF) had a median value of $1.6 billion in 2025 and averaged $1.8 billion.
  • The largest annual percentage gain for Pfizer's Depreciation & Amortization (CF) in the last 5 years was 3387.23% (2023), contrasted with its biggest fall of 5599.44% (2023).
  • Pfizer's Depreciation & Amortization (CF) (Quarter) stood at $3.9 billion in 2021, then fell by 8.07% to $3.5 billion in 2022, then crashed by 52.89% to $1.7 billion in 2023, then grew by 5.09% to $1.8 billion in 2024, then fell by 5.3% to $1.7 billion in 2025.
  • Its Depreciation & Amortization (CF) stands at $1.7 billion for Q3 2025, versus $1.6 billion for Q2 2025 and $1.6 billion for Q1 2025.